Nivolumab monotherapy represents an alternative first-line treatment option for treatment-naïve mRCC Presented ByDr Michael Atkins, Georgetown Lombardi Comprehensive Cancer Center, DC, USA TrialPhase 2, HCRN GU16-260 ConferenceASCO GU 2022 8 April, 2022 11:12